Last updated: 2026-09-30 08:41:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Femasys Inc. (FEMY) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $2.11, with a market capitalization of $19.93M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.00 to $22.20. This page covers its latest market performance, valuation, price trends and company information.
$19.93M | |
$2.36 | |
$275.00 | |
$2.00 | |
$2.38 | |
277.11K | |
724.15K | |
-- | |
$22.20 | |
$2.00 | |
-- | |
-- |
Femasys Inc. (FEMY) is trading at $2.37 in pre-market trading as of 2026-09-29 23:55:00, down 0.29% ($0.01) from the previous close of $2.38
Pre-market trading shows how investors are pricing FEMY before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, Femasys Inc. (FEMY) moved from $2.53 to $2.11, representing a decline of 16.80% ($0.42).
The stock traded between $2.00 and $2.69 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 82.68 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.5%
FEMY is currently trading at $2.11, placing it 0.5% of the way from its 52-week low of $2.00 to its 52-week high of $22.20. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 54 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Femasys Inc. (FEMY) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.